PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease

Ziekenhuis Oost-Limburg157 enrolled

Overview

To study the prevalence, non-invasive diagnostics and evolution of non-alcoholic-fatty-liver-disease (NAFLD) in patients with polycystic ovary syndrome (PCOS)

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

157

Conditions

NAFLD (Nonalcoholic Fatty Liver Disease)Polycystic Ovarian Syndrome (PCOS)

Interventions

FibroScanDIAGNOSTIC_TEST

Performance of a FibroScan measurement to determine the prevalence of liver steatosis.

MRI PDFFDIAGNOSTIC_TEST

Performance of an MRI-PDFF to determine amount of liver steatosis.

Eligibility

Sex: FEMALEMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Adults (i.e. older than 18 years of age) * The diagnosis of PCOS based on expert opinion (i.e. according to Rotterdam criteria) * Able to understand patients information concerning this study * Able to give written informed consent Exclusion Criteria: * Excessive alcohol use: ≥ 2u (20g)/day for females * Exclusion of other causes of liver disease * Secondary causes of liver steatosis * Other causes of endocrinological disease * Diseases that might mimic PCOS

Locations (1)

Ziekenhuis Oost-Limburg

Genk, Limburg, Belgium

Outcomes

Primary Outcomes

Prevalence of NAFLD

To study the prevalence of NAFLD in a population diagnosed with PCOS measured with Controlled Attenuation Parameter (CAP)

Time frame: Baseline and at follow-up 1 year later.

Prevalence of NAFLD in PCOS

To measure the prevalence of NAFLD in women with PCOS using the MRI-PDFF technique.

Time frame: Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.